The efficacy and safety of reduced-dosage rituximab in the treatment of neuromyelitis optica spectrum disorders under B cell monitoring-A prospective study
10.19845/j.cnki.zfysjjbzz.2021.0088
- VernacularTitle:一项B细胞监测下减量利妥昔单抗治疗视神经脊髓炎谱系病的前瞻性研究
- Author:
Yuanyuan LI
1
;
Hai YU
1
;
Xiaozhu WANG
1
Author Information
1. Department of Neurology,First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China
- Publication Type:Journal Article
- Keywords:
Neuromyelitis optica spectrum disorders;
Rituximab;
B cell monitoring;
Efficacy evaluation;
Security analysis
- From:
Journal of Apoplexy and Nervous Diseases
2021;38(4):345-348
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of a reduced-dosage rituximab (RTX) treatment regimen for neuromyelitis optica spectrum disorders (NMOSD) under B cell monitoring.Method Clinical data from 35 patients with NMOSD who were regularly followed up in the Department of Neurology of the First Affiliated Hospital of Soochow University from December 2016 to June 2019 were collected.They were divided into rituximab reduction group under B cell monitoring,azathioprine group and cyclophosphamide group.Differences in the indexes including the Expanded Disability Status Scale (EDSS) score,possibility of no recurrence,and adverse drug reactions were used to evaluate the efficacy and safety of the three treatment regimens.Results (1)The EDSS score of the RTX group was significantly lower than that of the AZA group before and after treatment (P<0.05).(2)The relapse risk of the RTX and CTX groups was significantly lower than that of the AZA group (Log-rank χ2=9.147,P=0.01).(3)The proportion of total adverse events in the RTX group was less than that in the CTX group.The glucocorticoids withdrawal rate in the RTX group was higher than that of the AZA group and the CTX group (P<0.05),and the difference was statistically significant.(4)The mean interval of treatment in RTX group was 7.00 (6.0,10.0) months.Conclusion The reduced-dose rituximab regimen under B cell monitoring is generally safe and effective in the treatment of NMOSD,which can prolong the medication interval and reduce the medication expenses of patients.
- Full text:2024073013291392337The efficacy and safety of reduced-dosage rituximab in the treatment of neuromyelitis optica spectrum disorders under B cell monitoring-A prospective study.pdf
